Author Archives: Fredricko
Vaxart to Present at World Vaccine Congress Europe 2022 on October 13
Read the rest here:
Vaxart to Present at World Vaccine Congress Europe 2022 on October 13
Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022
scPharmaceuticals Announces $100 Million Debt Financing Agreement with Oaktree
Supernus Provides Regulatory Update on SPN-830
Read the original here:
Supernus Provides Regulatory Update on SPN-830
Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with…
Biora Therapeutics to Participate in 12th Annual Partnership Opportunities in Drug Delivery Conference
UPDATE – scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop…
Enzo Biochem to Report Fourth Quarter 2022 Financial Results and Business Update on Friday, October 14th
Zealand Pharma major shareholder announcement: Van Herk Investments
View original post here:
Zealand Pharma major shareholder announcement: Van Herk Investments
DEINOVE – Extraordinary General Meeting of October 17, 2022: Appointment of an ad hoc representative
AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s…
NABP Enters Final Development Phase of DSCSA Interoperability Network
View original post here:
NABP Enters Final Development Phase of DSCSA Interoperability Network
Synergys Receives Third NIH SBIR Grant from National Cancer Institute
See the article here:
Synergys Receives Third NIH SBIR Grant from National Cancer Institute
AccuStem Announces Adjournment of Annual Meeting of Stockholders
Bone Therapeutics SA: Transparency notification received from S.F.P.I/F.P.I.M
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis
Roche launches PRAME (EPR20330) Antibody to identify PRAME protein expression in patients that may have melanoma
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic…
invIOs to present at upcoming industry and investor conferences
Read more from the original source:
invIOs to present at upcoming industry and investor conferences